Indications And Dose
Chronic hepatitis C infection (specialist use only) ▶BY MOUTH ▶Adult: 1 tablet once daily, for duration of treatment, consult product literature
PDF page 689
Loading InternPractice…
Drug reference
Chronic hepatitis C infection (specialist use only) ▶BY MOUTH ▶Adult: 1 tablet once daily, for duration of treatment, consult product literature
PDF page 689
DUE TO INTERACTIONS ▶Manufacturer advises reduce dose of concurrent H2- receptor antagonist if above a dose comparable to famotidine 40 mg twice daily. ▶Manufacturer advises reduce dose of concurrent proton pump inhibitor if above a dose comparable to omeprazole 20 mg.
PDF page 689
Hepatitis B co-infection
PDF page 689
NICE decisions ▶Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (February 2018) NICE TA507 Sofosbuvir with velpatasvir and voxilaprevir is recommended as an option for treating adults with chronic hepatitis C infection: . of genotype 1 to 6 with or without compensated cirrhosis (previously treated with direct-acting antivirals)—recommended for 12 weeks, or . of genotype 3 with or without compensated cirrhosis (no treatment history with direct-acting antivirals)— recommended for 8 weeks, and . the manufacturer provides the drug at the same price or lower than that agreed with the Commercial Medicines Unit. Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their NHS clinician consider it appropriate to stop. www.nice.org.uk/guidance/ta507 Scottish Medicines Consortium (SMC) decisions SMC No. 1317/18 The Scottish Medicines Consortium has advised (April 2018) that sofosbuvir with velpatasvir and voxilaprevir (Vosevi ®) is accepted for restricted use within NHS Scotland for the treatment of chronic hepatitis C virus (HCV) infection in adults who: . have failed to achieve a sustained virologic response Infection (SVR) with a direct-acting anti-viral (DAA), or . are DAA-naive, have genotype 3 (GT3) HCV infection, with or without cirrhosis, and are suitable for treatment with an eight-week course. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
PDF page 689
→Appendix 1: sofosbuvir. velpatasvir. voxilaprevir
PDF page 689
Manufacturer advises avoid in moderate to severe impairment.
PDF page 689
There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 21, 25 ▶Vosevi (Gilead Sciences International Ltd) A Velpatasvir 100 mg,Voxilaprevir 100 mg, Sofosbuvir 400 mg Vosevi 400mg/100mg/100mg tablets | 28 tablet P £14,942.33 ANTIVIRALS › PROTEASE INHIBITORS, HEPATITIS
PDF page 689
Vomiting Manufacturer advises if vomiting occurs within 4 hours of administration, an additional dose should be taken.
PDF page 689
1 tablet once daily, for duration of treatment,
First-line fragment. Read the complete Indications and Dose section above.
PDF page 689